Please typ	e a plus	s sign (+) inside this	s bo	x → _ +	Ar	oproved for us	e through	PTO/SB/08B (10 h 10/31/99. OMB 0651	-0031		
		ork Reduction Act o		995, no persons				EPARTMENT OF COMM n of information unless			
Substitute	for forr	n 1449A/PTO		-	Complete if Known						
					Application Number 09/759112						
INFORMATION DISCLOSURE					Filing Date		January 11, 2001				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					First named I						
					Group Art Uni Examiner Nan		Unknov				
Chan 1	l and '						Unknown 200-013				
3112		<u> </u>			Attorney Dock	ket Number	200-01	3	-		
NET T		-		IIS PATE	NT DOCUM	IENTS					
		U.S. Patent Docume	nt	U.S. I A I E	ANT DOCOM	Date of Public	cation of	Pages, Columns, Lin	es		
Examiner	Cite	Kin			tee or Applicant	Cited Docu	ment	Where Relevant Passag			
Initials*	No.1	Number Code	2	Of Cited I	Document	MM-DD-Y	YYY	Relevant Figures App	ear		
72		4,843,011		Sarngadhara	nn et al.						
/		5,217,895		Ohno							
		5,849,583		Muller et al.							
		6,057,421		Muller et al.	,						
								<u> </u>			
		OTHER PRIO	R A	RT-NON PA	ATENT LITE	ERATURE	DOCU	MENTS			
		Include name of the	ne a	uthor (in CAPITAL	L LETTERS), title	of the article (wi	nen appro	priate), title of the item			
Examiner Initials*	Cite No.1	(book, magazine, jo	urna	l, serial, symposiu	um, catalog, etc.), and/or country whe	date, page(s), v ere published	olume-iss	ue number(s), publisher,	Т6		
	110.1	S. MULLER, et	al				onal ant	i-idiotypic	,,,		
12		antibodies against human HIV-specific antibodies," J. Immunol. (1991) v147: 933-									
1		H. WANG, et al., "Human monoclonal and polyclonal anti-human									
immunodeficiency virus-1 antibodies share a common clonotypic specific											
37		J. Immunol. (19	•			common cro	notypic	specificity, Eur.			
/	V					<u> </u>	- 4 • .	1 1' ' C D			
-	-	B. HERNDIER, et al. "A Non-lymphoma idiotype is indicative and predictive for B									
3-			cell malignancies in AIDS," Hybridoma (1993) v12: 529-537. S. MULLER et al. "Stimulation of HIV-1-neutralizing antibodies in simian HIV-								
122											
5		IIIB-infected m									
		S. MULLER, et									
		expressed on an	tib	odies directed	l to envelope g	glycoprotein	in simia	an			

Examiner Signature	3 - 2	Date Considered	9/22/03

immunodeficiency virus- and chimeric simian/human immunodeficiency virus-

autoantibodies in human immunodeficiency virus-1-infected individuals," J. Clin.

S. CHAMAT et al., "Two major groups of neutralizing anti-gp120 antibodies exist

H. KOHLER et al., "Deceptive imprinting in the immune response against HIV-1"

Q. WANG, et al., "Identification of an idiotypic peptide recognized by

in HIV-infected individuals," J. Immunol. (1992) v149:649-654.

infected rhesus monkeys," Hybridoma (1997) v16: 17-21.

Invest. (1995) v96: 775-780.

(1994) v15: 475-478

*EXAMINER: Initial interest considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.